Dare Bioscience, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Dar Bioscience, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to elect directors, ratify auditor appointment, and vote on key corporate proposals including stock issuance and equity plan amendments.
NASDAQ
DEFA14A: Dar Bioscience Adjourns Annual Stockholders Meeting Due to Lack of Quorum, Reschedules for July 9
Dar Bioscience, Inc. announced the adjournment of its 2025 annual meeting of stockholders due to a lack of the required quorum, with the meeting now set to reconvene virtually on Wednesday, July 9, 2025.
NASDAQ
DAR Bioscience, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
Dar Bioscience is holding its 2025 Annual Meeting of Stockholders on June 12, 2025, to vote on director elections, auditor ratification, executive compensation, and an amendment to the 2022 Stock Incentive Plan.
NASDAQ
DAR Bioscience, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
DEF 14A: Dar Bioscience Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance
Dar Bioscience is asking stockholders to approve a reverse stock split proposal to regain compliance with Nasdaq's minimum bid price requirement.